Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib inRAS-mutant relapsed or refractory myeloid malignancies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib inRAS-mutant relapsed or refractory myeloid malignancies

Published:2016-03-18 Issue:12 Volume:122 Page:1871-1879
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Borthakur Gautam¹,Popplewell Leslie²,Boyiadzis Michael³,Foran James⁴,Platzbecker Uwe⁵,Vey Norbert⁶,Walter Roland B.⁷,Olin Rebecca⁸,Raza Azra⁹,Giagounidis Aristoteles¹⁰,Al-Kali Aref¹¹,Jabbour Elias¹,Kadia Tapan¹,Garcia-Manero Guillermo¹,Bauman John W.¹²,Wu Yuehui¹³,Liu Yuan¹⁴,Schramek Dan¹⁵,Cox Donna S.¹⁶,Wissel Paul¹⁷,Kantarjian Hagop¹

Affiliation:

1. The University of Texas MD Anderson Cancer Center; Houston Texas

2. City of Hope Medical Center; Duarte California

3. University of Pittsburgh Cancer Institute; Pittsburgh Pennsylvania

4. University of Alabama Hospital; Birmingham Alabama

5. Carl Gustav Carus University Hospital; Dresden Germany

6. Paoli-Calmettes Institute; Marseille France

7. Fred Hutchinson Cancer Research Center; Seattle Washington

8. University of California San Francisco; San Francisco California

9. Columbia University Medical Center; New York New York

10. Marien Hospital; Dusseldorf Germany

11. Mayo Clinic; Rochester New York

12. Quintiles; Durham North Carolina

13. Merck & Company, Incorporated; North Wales Pennsylvania

14. Pfizer Oncology; La Jolla California

15. GlaxoSmithKline; Collegeville Pennsylvania

16. Teva Pharmaceuticals; Frazier Pennsylvania

17. Pfizer, Incorporated; Collegeville Pennsylvania

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.29986/fullpdf

Reference27 articles.

1. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia;Milella;J Clin Invest.,2001

2. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia;Ricciardi;Leukemia.,2005

3. Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for “vertical” and “lateral” combination strategies;Ricciardi;J Mol Med (Berl).,2012

4. Inhibition of overactivated P38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors;Navas;Blood.,2006

5. The incidence and prognostic significance of mutations in codon 13 of the N-Ras gene in acute myeloid leukemia;Coghlan;Leukemia.,1994

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia;Biomedicines;2024-08-06

2. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial;Clinical Lymphoma Myeloma and Leukemia;2024-06

3. In vivo Targeting MEK and TNK2/SRC pathways in PTPN11 driven leukemia;2024-05-18

4. FLT3-Mutated Leukemic Stem Cells: Mechanisms of Resistance and New Therapeutic Targets;Cancers;2024-05-10

5. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management;American Journal of Hematology;2024-04-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3